HeartWare International Inc. (NASDAQ:HTWR) Receives $51.44 Consensus PT from Brokerages
Shares of HeartWare International Inc. (NASDAQ:HTWR) have been given an average recommendation of “Hold” by the eighteen ratings firms that are presently covering the company. Thirteen research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $51.44.
Several equities analysts have recently commented on the stock. BTIG Research reissued a “hold” rating on shares of HeartWare International in a report on Thursday, August 25th. Zacks Investment Research downgraded shares of HeartWare International from a “buy” rating to a “hold” rating in a report on Tuesday, August 16th. Canaccord Genuity reissued a “buy” rating and issued a $58.00 target price on shares of HeartWare International in a report on Thursday, July 28th. Raymond James Financial Inc. downgraded shares of HeartWare International from an “outperform” rating to a “market perform” rating in a report on Wednesday, July 13th. Finally, Leerink Swann downgraded shares of HeartWare International from an “outperform” rating to a “market perform” rating and set a $58.00 target price on the stock. in a report on Monday, July 11th.
In other news, VP Mark Strong sold 1,875 shares of the company’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $57.71, for a total value of $108,206.25. Following the transaction, the vice president now directly owns 5,388 shares in the company, valued at $310,941.48. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Peter F. Mcaree sold 3,125 shares of the company’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $57.68, for a total transaction of $180,250.00. Following the completion of the transaction, the chief financial officer now owns 22,130 shares in the company, valued at $1,276,458.40. The disclosure for this sale can be found here.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pacad Investment Ltd. acquired a new stake in HeartWare International during the first quarter worth $273,000. TIAA CREF Investment Management LLC raised its stake in HeartWare International by 73.7% in the first quarter. TIAA CREF Investment Management LLC now owns 130,433 shares of the company’s stock worth $4,098,000 after buying an additional 55,344 shares during the period. Continental Advisors LLC raised its stake in HeartWare International by 92.6% in the first quarter. Continental Advisors LLC now owns 41,600 shares of the company’s stock worth $1,307,000 after buying an additional 20,000 shares during the period. Franklin Resources Inc. raised its stake in HeartWare International by 1.9% in the first quarter. Franklin Resources Inc. now owns 579,967 shares of the company’s stock worth $18,222,000 after buying an additional 11,036 shares during the period. Finally, Menta Capital LLC acquired a new stake in HeartWare International during the first quarter worth $268,000.
Shares of HeartWare International (NASDAQ:HTWR) opened at 57.98 on Friday. The firm’s 50-day moving average is $57.82 and its 200 day moving average is $39.18. HeartWare International has a 12 month low of $25.02 and a 12 month high of $87.38.
HeartWare International (NASDAQ:HTWR) last issued its quarterly earnings results on Thursday, July 28th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.39. The firm had revenue of $68.72 million for the quarter, compared to analysts’ expectations of $57.36 million. During the same period in the prior year, the firm earned ($0.47) EPS. HeartWare International’s revenue for the quarter was down 6.6% compared to the same quarter last year. Equities analysts anticipate that HeartWare International will post ($3.07) earnings per share for the current year.
About HeartWare International
Heartware International, Inc is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices.
Receive News & Ratings for HeartWare International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartWare International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.